S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
Something is Coming for America's Top Stock (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
Something is Coming for America's Top Stock (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
This Little Known Automaker May Save Your Life and Your Portfolio
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
Something is Coming for America's Top Stock (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
Something is Coming for America's Top Stock (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
This Little Known Automaker May Save Your Life and Your Portfolio
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
Something is Coming for America's Top Stock (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
Something is Coming for America's Top Stock (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
This Little Known Automaker May Save Your Life and Your Portfolio
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
Something is Coming for America's Top Stock (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
Something is Coming for America's Top Stock (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
This Little Known Automaker May Save Your Life and Your Portfolio
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
NASDAQ:ACXP

Acurx Pharmaceuticals (ACXP) Stock Forecast, Price & News

$1.41
-0.09 (-6.00%)
(As of 09/27/2023 ET)
Compare
Today's Range
$1.35
$1.50
50-Day Range
$1.41
$2.22
52-Week Range
$1.35
$4.61
Volume
44,419 shs
Average Volume
31,582 shs
Market Capitalization
$18.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

Acurx Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
822.0% Upside
$13.00 Price Target
Short Interest
Healthy
0.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of Acurx Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.08) to ($0.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

199th out of 976 stocks

Pharmaceutical Preparations Industry

74th out of 453 stocks


ACXP stock logo

About Acurx Pharmaceuticals (NASDAQ:ACXP) Stock

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.

ACXP Price History

ACXP Stock News Headlines

H.C. Wainwright Sticks to Its Buy Rating for Acurx Pharmaceuticals (ACXP)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Maxim Group Remains a Buy on Acurx Pharmaceuticals (ACXP)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
See More Headlines
Receive ACXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACXP Company Calendar

Last Earnings
8/14/2023
Today
9/27/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACXP
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.00
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+815.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-12,090,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.63 per share

Miscellaneous

Free Float
8,414,000
Market Cap
$18.47 million
Optionable
Not Optionable
Beta
-1.00
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Robert J. DeLucciaMr. Robert J. DeLuccia (Age 77)
    Co-Founder & Exec. Chairman
    Comp: $677.19k
  • Mr. David P. Luci CPAMr. David P. Luci CPA (Age 56)
    CPA, Esq., J.D., Co-Founder, Pres, CEO, Corp. Sec. & Director
    Comp: $655k
  • Mr. Robert G. Shawah CPA (Age 56)
    CPA, Co-Founder & CFO
    Comp: $375k













ACXP Stock - Frequently Asked Questions

Should I buy or sell Acurx Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acurx Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACXP shares.
View ACXP analyst ratings
or view top-rated stocks.

What is Acurx Pharmaceuticals' stock price forecast for 2023?

2 Wall Street analysts have issued 1-year target prices for Acurx Pharmaceuticals' shares. Their ACXP share price forecasts range from $13.00 to $13.00. On average, they expect the company's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 815.5% from the stock's current price.
View analysts price targets for ACXP
or view top-rated stocks among Wall Street analysts.

How have ACXP shares performed in 2023?

Acurx Pharmaceuticals' stock was trading at $3.98 at the beginning of the year. Since then, ACXP shares have decreased by 64.3% and is now trading at $1.42.
View the best growth stocks for 2023 here
.

Are investors shorting Acurx Pharmaceuticals?

Acurx Pharmaceuticals saw a drop in short interest during the month of September. As of September 15th, there was short interest totaling 6,700 shares, a drop of 51.1% from the August 31st total of 13,700 shares. Based on an average trading volume of 35,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.1% of the company's shares are short sold.
View Acurx Pharmaceuticals' Short Interest
.

When is Acurx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ACXP earnings forecast
.

How were Acurx Pharmaceuticals' earnings last quarter?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) released its quarterly earnings results on Monday, August, 14th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. During the same period last year, the company earned ($0.26) earnings per share.

When did Acurx Pharmaceuticals IPO?

(ACXP) raised $15 million in an IPO on Friday, June 25th 2021. The company issued 2,500,000 shares at $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities served as the underwriters for the IPO.

What is Acurx Pharmaceuticals' stock symbol?

Acurx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACXP."

Who are Acurx Pharmaceuticals' major shareholders?

Acurx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Osaic Holdings Inc. (0.17%), Osaic Holdings Inc. (0.17%) and One68 Global Capital LLC (0.10%). Insiders that own company stock include Carl Sailer, David P Luci and Robert J Deluccia.
View institutional ownership trends
.

How do I buy shares of Acurx Pharmaceuticals?

Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acurx Pharmaceuticals' stock price today?

One share of ACXP stock can currently be purchased for approximately $1.42.

How much money does Acurx Pharmaceuticals make?

Acurx Pharmaceuticals (NASDAQ:ACXP) has a market capitalization of $18.47 million. The company earns $-12,090,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis.

How can I contact Acurx Pharmaceuticals?

The official website for the company is www.acurxpharma.com. The company can be reached via phone at 917-533-1469 or via email at davidluci@acurxpharma.com.

This page (NASDAQ:ACXP) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -